One-year outcomes of thoracic endovascular stent graft repair for acute type B aortic penetrating ulcer combined with antiplatelet drugs - Scorecard - MDSpire
Advertisement
One-year outcomes of thoracic endovascular stent graft repair for acute type B aortic penetrating ulcer combined with antiplatelet drugs
Clinical Scorecard: Twelve-Month Clinical Outcomes Following Thoracic Endovascular Aortic Repair for Acute Type B Aortic Penetrating Ulcers with Antiplatelet Therapy
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Care Setting
Key Highlights
Study included 195 patients, with 59 treated with antiplatelet drugs.
15.8% experienced major adverse events within 12 months.
No significant differences in imaging parameters between AP and NAP groups at 6 months.
Maximum aortic diameter, PAU diameter ≥ 10.5 mm, and PAU depth ≥ 7.5 mm were associated with major adverse events.
Antiplatelet therapy may be safe for patients with acute PAUs post-TEVAR.
Guideline-Based Recommendations
Diagnosis
Management
Standardized clinical protocol for management post-diagnosis, as per 2014 consensus guidelines.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Antiplatelet therapy is recommended for the chronic phase of PAUs, according to the 2014 consensus guidelines.
Clinical Best Practices
Conduct procedures following standardized institutional protocols.
Ensure operators have significant experience in TEVAR.
